Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 19, 2009
Wed, February 18, 2009 Dyax Corp. to Host Fourth Quarter and Year End 2008 Earnings Call and Webcast
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Dyax Corp. (NASDAQ:DYAX) will host a webcast and conference call, including an open question and answer session, Wednesday, February 25, 2009, to discuss its financial results and company progress for the fourth quarter and year ended December 31, 2008.
Date: | Wednesday, February 25, 2009 | |
Time: | 10:00 a.m. ET | |
Telephone Access: | Domestic callers, dial 866-953-0762 | |
| International callers, dial 617-399-3492 | ||
| Passcode 69206150 | ||
Online Access: | Go to the Investor Relations section of the Dyax website ([ www.dyax.com ]) and follow instructions for accessing the live webcast. Participants may register in advance. |
A replay of the conference call will be available through March 25, 2009 and may be accessed by dialing 888-286-8010.International callers should dial 617-801-6888. The replay passcode for all callers is 30990771. The webcast will be archived on the Dyax website for an indefinite period of time.
About Dyax
Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax's lead product candidate is DX-88 (ecallantide), a recombinant small protein that is currently being evaluated for its therapeutic potential in two separate indications. On September 23, 2008, Dyax submitted its Biologics License Application to the U.S. Food and Drug Administration for approval of DX-88 for the treatment of hereditary angioedema (HAE). DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S., for the treatment of acute attacks of HAE. Additionally, DX-88 is being evaluated for the prevention of blood loss during on-pump cardiothoracic surgery (CTS) through its partner, Cubist Pharmaceuticals. Dyax licensed to Cubist the intravenous formulation of DX-88 for surgical indications in North America and Europe. DX-88 and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit [ www.dyax.com ].
